Neuromyelitis Optica Spectrum Disorder

Research output: Contribution to journalReview articlepeer-review


The canonical clinical features of neuromyelitis optica have been supplemented by other characteristic syndromes and the finding of pathogenic AQP4-IgG autoantibodies. The expanded disease spectrum, NMOSD, is treated with drugs that target the steps in pathogenesis. Promising approaches to predicting and preventing relapses, enhancing recovery from relapse, and achieving immune tolerance are under investigation.

Original languageEnglish (US)
Pages (from-to)631-639
Number of pages9
JournalNew England Journal of Medicine
Issue number7
StatePublished - Aug 18 2022

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Neuromyelitis Optica Spectrum Disorder'. Together they form a unique fingerprint.

Cite this